UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB
                                   (Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE PERIOD ENDED March 31, 2003
                                       OR
[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD From                          to.


                        Commission File Number 333-60362

                             NEURO BIOSCIENCE, INC.
                             ----------------------
             (Exact name of registrant as specified in its charter)
                          Filed Effective May 14, 2003

                    Utah                                   87-0670014
                    ----                                   ----------
     (State or other jurisdiction of                    (I.R.S. Employer
     incorporation or organization)                    Identification No.)


                           1251 Avenue of the Americas
                              35th Floor, Suite 29
                               New York, NY 10020
                               ------------------
                    (Address of principal executive officers)
                               (212)  591-0256
                               ---------------
               (Registrant's telephone number, including area code)


                                 Not Applicable
                                 --------------
   (Former name, former address and former fiscal year, if changed since last
                                     report)

Indicate by check mark whether the registrant (l) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter periods that the registrant was
required to file such reports),    X Yes       No ____; and (2) has been subject
to such filing requirements for the past 90 days:   X Yes      _ No ____


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS


Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13, or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by the court. Yes  No    Not Applicable


                      APPLICABLE ONLY TO CORPORATE ISSUERS


Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practical date.

Common Stock: 10,069,300 shares issued as of May 14, 2003.  No Par Value.
Authorized - 50,000,000 common voting shares.  The company has only one class of
shares.


                                        1


                                      INDEX

                             Neuro Bioscience, Inc.
                      For the Quarter Ending March 31, 2003


Part I.  Financial Information

     Item 1.   Financial Statements

     Item 2.   Management's Discussion and Analysis of Financial
               Condition and Results of Operations

     Item 3.   Controls and Procedures


Part II.  Other Information

     Item 5.   Other Matters

     Item 6.   Exhibits and Reports on Form 8-K

Signatures

Certifications


                                        2




                     Part I-Unaudited Financial Information


Item 1.  Unaudited Financial Statements

The  financial statements included herein have been prepared in conformity  with
accounting  principles generally accepted in the United States of America.   The
statements are unaudited, but reflect all adjustments, which, in the opinion  of
management, are necessary to fairly present the Company's financial position and
results of operations.  All such adjustments are of a normal recurring nature.


                             NEURO BIOSCIENCE, INC.
                          (A Development Stage Company)


                                TABLE OF CONTENTS



                                                                           Page

Consolidated Financial Statements:

     Condensed Consolidated Balance Sheets - March 31, 2003 and
       December 31, 2002 (Unaudited)                                          3


     Condensed Consolidated Statements of Operations for the Three Months
       Ended March 31, 2003 and 2002 and for the Period from December 31,
       2001 (Date of Inception) through March 31, 2003 (Unaudited)            4


     Condensed Consolidated Statements of Cash Flows for the Three Months
       Ended March 31, 2003 and 2002 and for the Period from December 31,
       2001 (Date of Inception) through March 31, 2003 (Unaudited)            5


Notes to Condensed Consolidated Financial Statements (Unaudited)              6



                                        3


NEURO BIOSCIENCE, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED CONDENSED BALANCE SHEET
(Unaudited)

<TABLE>
<CAPTION>

                                                                 March 31,          December 31,
                                                                      2003                  2002
------------------------------------------------------------------------------------------------

                                                            <c>                 <c>
ASSETS

Current Assets
Cash                                                            $        -          $      8,809
Other assets                                                           156                   156
------------------------------------------------------------------------------------------------

Total Current Assets                                                   156                 8,965
------------------------------------------------------------------------------------------------

Total Assets                                                    $      156          $      8,965
================================================================================================

LIABILITIES AND STOCKHOLDER'S DEFICIT

Current Liabilities
Accounts payable                                                $1,075,002          $    855,404
Related party payables                                             450,000               450,000
Accrued expenses                                                   154,778                22,778
------------------------------------------------------------------------------------------------

   Total Current Liabilities                                     1,679,780             1,328,182
------------------------------------------------------------------------------------------------

Stockholders' Deficit
Common stock, no par value; 50,000,000 shares
authorized; 10,069,300 shares issued and outstanding                10,069                10,069
Additional paid-in capital                                         324,285               213,523
Accumulated deficit                                             (2,013,978)           (1,542,809)
------------------------------------------------------------------------------------------------

   Total Stockholders' Deficit                                  (1,679,624)           (1,319,217)
------------------------------------------------------------------------------------------------

Total Liabilities and Stockholders' Deficit                     $      156          $      8,965
================================================================================================




</TABLE>


See the accompanying notes to the condensed consolidated financial statements.

                                        4



NEURO BIOSCIENCE, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(Unaudited)

<TABLE>
<CAPTION>

                                                                                     For the Period From
                                            For the                For the             Decemer 31, 2001
                                         Three Months            Three Months        (Date of Inception)
                                        Ended March 31,        Ended March 31,         through March 31,
--------------------------------------------------------------------------------------------------------
                                             2003                   2002                     2003
--------------------------------------------------------------------------------------------------------

                                    <c>                     <c>                     <c>


Revenue                                 $            -          $           -           $            -

Operating Expenses
Research and development                       282,000                225,000                1,107,000
Consulting expense                              30,000                 42,915                  130,000
General and administrative expenses            166,253                114,418                  759,465
------------------------------------------------------------------------------------------------------

Total Operating Expenses                       478,253                382,333                1,996,465

Foreign Currency exchange
 gain (loss), net                                7,084                    257                  (17,513)
-------------------------------------------------------------------------------------------------------

Net Loss                                $     (471,169)         $    (382,076)          $   (2,013,978)
=======================================================================================================

Basic and Diluted Loss Per Share        $        (0.05)         $       (0.04)
-----------------------------------------------------------------------------

Weighted Number of Shares
 Shares Outstanding                         10,069,300              9,000,000
-----------------------------------------------------------------------------



</TABLE>


See the accompanying notes to the condensed consolidated financial statements.

                                        5



NEURO BIOSCIENCE, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)

<TABLE>
<CAPTION>

                                                                                                          For the Period From
                                                              For the                For the               Decemer 31, 2001
                                                           Three Months           Three Months            (Date of Inception)
                                                          Ended March 31,        Ended March 31,           through March 31,
----------------------------------------------------------------------------------------------------------------------------
                                                               2003                   2002                       2003
----------------------------------------------------------------------------------------------------------------------------

                                                    <c>                     <c>                   <c>

Cash Flows from Operating Activities
Net loss                                               $     (471,169)         $    (382,076)        $         (2,013,978)
Stock issued for services                                           -                      -                      100,000
Contributed officer's services                                      -                 30,000                      120,000
Warrants issued for services                                  110,762                      -                      110,762
Changes in current liabilities:
Accounts payable and accrued expenses                         358,682                127,333                    1,205,349
Related party payables                                              -                225,000                      450,000
-------------------------------------------------------------------------------------------------------------------------

Net Cash Used by Operating Activities                          (1,725)                   257                      (27,867)
-------------------------------------------------------------------------------------------------------------------------

Cash Flows from Investing Activities
Cash acquired in purchase of MPLS Corporation                       -                      -                       10,354
-------------------------------------------------------------------------------------------------------------------------

Net Cash Provided by Investing Activities                           -                      -                       10,354
-------------------------------------------------------------------------------------------------------------------------

Cash Flows from Financing Activities                                -                      -                            -
-------------------------------------------------------------------------------------------------------------------------

Effect of Exchange Rate Changes on Cash                        (7,084)                  (257)                      17,513
-------------------------------------------------------------------------------------------------------------------------

Net Increase in Cash                                           (8,809)                     -                            -

Cash at Beginning of Period                                     8,809                      -                            -
-------------------------------------------------------------------------------------------------------------------------

Cash at End of Period                                  $            -          $           -         $                  -
=========================================================================================================================

Non Cash Investing and Financing Activities
Common stock issued for receivable                     $            -          $         156         $                156



</TABLE>


See the accompanying notes to the condensed consolidated financial statements.

                                        6


                               NEURO BIOSCIENCE, INC.
                            (A Development Stage Company)
                   NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                  March 31, 2003
                                   (Unaudited)

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Condensed   Financial   Statements  -  The  accompanying   unaudited   condensed
consolidated financial statements include the accounts of Neuro Bioscience, Inc.
and  its  subsidiaries (the "Company"). These financial statements are condensed
and,  therefore, do not include all disclosures normally required by  accounting
principles generally accepted in the United States of America.  These statements
should  be  read  in conjunction with the Company's annual financial  statements
included  in the Company's December 31, 2002 Annual Report on Form  10-KSB.   In
particular,  the Company's significant accounting principles were  presented  as
Note  2  to the consolidated financial statements in that report. In the opinion
of  management,  all  adjustments necessary for a fair  presentation  have  been
included  in  the accompanying condensed consolidated financial  statements  and
consist  of  only  normal  recurring adjustments.   The  results  of  operations
presented  in  the accompanying condensed consolidated financial statements  for
the  three  months  ended March 31, 2003 are not necessarily indicative  of  the
results that may be expected for the full year ending December 31, 2003.

NOTE 2 - BUSINESS CONDITION

The  accompanying  financial statements have been prepared on  a  going  concern
basis,  which  contemplates the realization of assets and  the  satisfaction  of
liabilities  in the normal course of business. During the period  from  December
31,  2001 (Date of inception) through March 31, 2003, the Company incurred a net
loss  and  accumulated deficit of $2,013,978 and used cash  from  operations  of
$27,867. As of March 31, 2003, the Company had not generated any revenues. These
factors, among others, indicate that the Company may be unable to continue as  a
going  concern.  The  accompanying  financial  statements  do  not  include  any
adjustments  relating  to  the carrying amount and  classification  of  recorded
assets  or  the amount and classification of liabilities that might be necessary
should  the  Company  be  unable to continue as a going concern.  The  Company's
ability to continue as a going concern is dependent upon its ability to generate
sufficient  cash  flows  to meet its obligations on a timely  basis,  to  obtain
additional  financing  and  ultimately to  attain  successful  operations.   The
Company's  management  intends to raise additional financing  through  a  public
offering.  There is no assurance that additional financing will be obtained.

NOTE 3 - STOCKHOLDERS' EQUITY

As part of the Stock Exchange Agreement with MPLS, in the event that the Company
had  not  obtained  financing  of at least $5 million  within  60  days  of  the
agreement  (November 14, 2002), the former directors of MPLS were to  be  issued
warrants  to  purchase common stock of the Company.  Due to  funding  not  being
obtained within the 60 day period, the 503,465 warrants were effectively  issued
to  the  former  directors January 14, 2003.  The warrants were valued  at  fair
market  value  of  $0.22  per share or $110,762 using the  Black-Scholes  option
pricing model.

NOTE 4 - LICENSING AGREEMENTS

The  Company  has  five  exclusive licensing agreements with  various  companies
relative  to patents and patent applications. Under the terms of the agreements,
the  Company is required to pay a royalty ranging from 4% to 10% of  net  sales.
Under  the terms of two of the licensing agreements, 400,000 and 200,000  shares
of  common  stock were to be issued within 90 days of the agreements, or  during
January  and  February  2003, respectively.  The Company intends  to  issue  the
shares  once  the next stage of development of the products has been  completed.
The  value  of  the shares to be accrued based on the fair market value  of  the
common stock of $0.22 per share is $88,000 and $44,000, respectively.


                                        7

NOTE 5 - MERGER

On  March 31, 2003, the Company entered into a merger agreement with CLL  PHARMA
SA  ("CLL"),  a French corporation that is developing generic drug products  and
drug delivery systems.  As of the effective date of the merger, the Company will
acquire up to 100% of CLL.  The shareholders of CLL will receive up to 8,000,000
shares of the Company's common stock.  The merger agreement was not finalized as
of May 14, 2003.

NOTE 6 - CONSULTING AGREEMENT

On  January  1,  2003, the Company entered into an agreement with  a  consulting
group  to  provide financial services.  As part of the agreement, the  Company's
current President, Alan Bowen, will act as Chief Financial Officer and President
of  the  Company.  The fee for these services will be $10,000 per  month,  which
will increase to $15,000 per month when the Company completes a public offering.

NOTE 7 - COMMITMENTS

On  March  1,  2003,  the  Company entered into an agreement  with  a  financial
services  group to act in the capacity of a financial advisor.  Under the  terms
of  the  agreement, a retainer of $9,000 per month will be accrued  and  250,000
warrants  will  be  issued.  The retainer will be paid and the  warrants  issued
either  when  a  public or private debt or equity financing is  completed  or  a
merger  or acquisition is completed.  In addition, if a debt or equity financing
occurs  during  the  term of the agreement, the Company will pay  the  financial
services  group  a success fee of 7% of the value of the transaction  and  issue
warrants  equal  to  10%  of  the value of the  transaction.   If  a  merger  or
acquisition  takes place, that was introduced by the financial  services  group,
the  Company shall pay a success fee of 5% and issue warrants equal to 3% of the
value of the transaction.


                                        8




Item 2.   Management's Discussion and Analysis of Financial Condition or Plan
           of Operation

Forward Looking Information

Certain statements in this Section and elsewhere in this report are forward-
looking in nature and relate to trends and events that may affect the Company's
future financial position and operating results.  Such statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.  The terms "expect", "intend", and "project" and similar
words or expressions are intended to identify forward-looking statements.  These
statements speak only as of the date of this report.  The statements are based
on current expectations, are inherently uncertain, are subject to risks, and
should be viewed with caution.  Actual results from experience may differ
materially from the forward-looking statements as a result of many factors,
including changes in economic conditions in the markets served by the company,
increasing competition, fluctuations in raw materials and energy prices and
other unanticipated events and conditions.  It is not possible to foresee or
identify all such factors.  The company makes no commitment to update any
forward-looking statement or to disclose any facts, events, or circumstances
after the date hereof that may affect the accuracy of any forward-looking
statement.

History and General Description of Operations

Neuro Bioscience, Inc. ("Neuro") became a public entity on approximately
November 14, 2002 upon the completion of an acquisition of Neuro Bioscience,
Inc., a privately held Delaware corporation, by an inactive public corporation
known as Mortgage Professionals Lead Source, Inc. ("MPLS") after which share
acquisition the name of the public corporation was changed to Neuro Bioscience,
Inc. and it assumed, as its sole business activities, the business of Neuro as
its sole operating subsidiary. This type of reorganization is sometimes referred
to as a "reverse acquisition" since the surviving company takes on the name, all
of the attributes, business and appoints management directly selected by the
acquired company as part of the reorganization.

MPLS was incorporated in Utah on February 16, 2001 and completed an initial
public offering of its securities in December, 2001, raising approximately
$109,300 of net proceeds from this offering pursuant to an SB-2 registration
filing which also became effective in the state of Utah by coordination.

In September, 2002 MPLS entered into a Letter of Intent to acquire the product
and assets of Neuro Bioscience of Delaware. The essential terms of this
acquisition provided that the public company, MPLS, would change its name of
record in Utah to Neuro Bioscience, have a new board of directors elected by a
special shareholder meeting incident to the reorganization as nominated by the
then current management of Neuro Bioscience. Neuro Bioscience of Delaware would
then operate as the sole business subsidiary for the development of the
pharmaceutical products and processes. Neuro Bioscience, Inc., which would
remain a Delaware corporation, would be wholly owned by the prior MPLS. Neuro
Bioscience of Delaware has subsequently changed its name to Neuro Acquisition



                                        9


Corporation to avoid confusion with its parent. With this description of the
reorganization, all subsequent references in this quarterly report to Neuro or
Neuro Bioscience, Inc. shall mean the publicly held Utah Corporation for which
this report is being completed, unless the subsidiary is specifically
identified. The reorganization was completed and ratified by shareholder vote on
November 14, 2002. Articles of Name Change for MPLS to Neuro Bioscience were
filed in Utah on November 18, 2002.

Neuro Bioscience of Delaware has a wholly owned subsidiary in Great Britain
known as Neuro Bioscience Limited, a privately held and chartered corporation in
Great Britain which is wholly owned by Neuro Bioscience of Delaware. This
subsidiary was previously known as European Life Science Research Limited and
was incorporated on December 9, 1997. Since April 8, 2002 it has been known as
Neuro Bioscience Limited and will be referred to in this report as Neuro
Bioscience of Britain. The essential purpose of this subsidiary is to provide on
site management review and supervision of the license rights and product
development obligations entered by Neuro Bioscience of Delaware. Since most of
the licensors of the Pharmaceutical Products are British entities, it has been
deemed historically appropriate to have an on-site supervision and management
entity to supervise the operation and development of the pharmaceutical products
and processes pursuant to these license agreements.

By way of current general description, all operations and directions of the
company are now vested in the board of directors of Neuro which fully oversees
and directs the operations of its sole operating subsidiary, Neuro Bioscience of
Delaware, which in turn is the licensee of the six principal pharmaceutical
products or processes currently under development by the company. Neuro
Bioscience of Britain, as a wholly owned subsidiary of Neuro Bioscience of
Delaware, continues to provide on-site management and supervision of the
implementation of the license rights and product development in Great Britain
with the various licensors. Neuro Bioscience of Great Britain has one director
and principal officer who is also a director and principal officer in Neuro
Bioscience of Delaware and Neuro Bioscience, the public entity, thereby
providing a direct line of responsibility and reporting as to the field
activities of the company.

Neuro may consider, but has not finally determined to complete, a formal
statutory merger between Neuro Bioscience of Delaware and the parent company in
the future. Any such event would, of course, be reported as required by various
state laws, as well as reporting requirements under the Securities and Exchange
Act of 1934 to shareholders as part of a closed end merger, if and when such
action is taken by the board of directors.

The Company is also considering, during the current calendar year of 2003, the
possibility of upgrading its current stock exchange listing from the current
Electronic Bulletin Board as sponsored by the National Association Securities
Dealers (NASD) to the newly sponsored and proposed BBX Listing also to be
administered by the NASD. Any company, as part of a BBX Listing, would be
required to propose and adopt certain reorganizational matters to its structure
including the designation of an independent audit committee. Neuro is currently
reviewing those requirements and the prospects of a proposed BBX Listing. Again,
any shareholder would be advised through notice and any required voting on
proposals incident to such listing as required by both state corporate law and
34' Act requirements.


                                        10


As presently constituted Neuro has 50,000,000 common shares authorized at $0.001
par value. There are no other classes or series of shares. Of the 10,069,300
common shares presently outstanding, approximately 9,000,000 shares are issued
to 8 shareholders. These shareholders are primarily entities having a direct or
indirect interest in the pharmaceutical products and procedures of the company
and all of them are foreign corporations, principally located in Great Britain.
Collectively, these shareholders now own 89.1% of the issued and outstanding
shares of the company. Approximately 10% is held by prior principals and
affiliates, who held shares prior to the reverse acquisition transaction, and
the remaining 0.9% is held by the public.

In summary, Neuro is essentially controlled by the group of eight principal
shareholders located in the USA and Europe and should remain under their control
for the foreseeable future.

Neuro presently does not have any stock rights or options authorized or issued.
It would be anticipated, as part of the needs of the company to raise interim
funding, some portion of the authorized but unissued shares will be issued in
the future if these funding efforts are successful. No present agreement,
offering or arrangement to place shares presently exits.


Products and Markets

Neuro is an emerging biotechnology company that is focused on the discovery,
development and commercialization of drugs or procedures to treat diseases and
disorders of the human central nervous system, generically "CNS" Drugs or
processes. The Company has license and development rights to products targeted
against Alzheimer's, Depression, Multiple Sclerosis, and Parkinson's Disease.
The Company will seek to develop these products by entering into co-development,
licensing and marketing agreements with pharmaceutical partners.

Neuro currently does not have any revenues to complete the development,
licensing and marketing of its six pharmaceutical products and processes. As a
result, the Company will continue with its limited present capital resources as
per its credit agreement with Jano Holdings Limited to maintain current
operations of the corporation and to engage in limited licensing compliance
procedures. However, before significant progress can be made in the licensing or
development process of each of the pharmaceutical products, the Company will be
required to raise significant additional capital.

Liquidity and Sources of Capital

Jano Holdings, Ltd. is a privately held Gibraltar corporation which is providing
an initial line of credit funding for the company as described below.


                                        11


In August 2001, the Company obtained a secured financing facility with Jano
Holdings for $2,000,000, bearing interest at a rate of 7% per annum. The
Facility provides for up to $2,000,000 in short term financing available in
several tranches, subject to criteria, conditions and covenants set forth in the
agreement. The Facility is secured by the pledge of the assets of the Company.
It is anticipated this credit facility will provide initial operating capital
for approximately the next eight months.  A copy of this agreement has been
earlier filed.

The Company has signed a preliminary agreement to acquire CLL Pharma SA, which
as of the current time has not closed.  This proposed acquisition agreement, if
closed, is more fully set-out in a copy of the agreement filed as part of
Neuro's 10-KSB filing and will be the subject of a subsequent 8-K filing.

Plan of Operation

The Company primarily intends to raise additional capital by seeking out
potential institutional or private investors who would invest funds on a private
placement basis. Since no current offering has been outlined or implemented, no
specific description is possible, at the present time, concerning the form,
amounts or terms of such anticipated private placement. The Company would intend
that any such private placement would primarily consist of its common stock
which would be sold as restricted common stock in a private placement offering
either in the United States or Great Britain or some combination of these
jurisdictions. It is possible, though not presently anticipated; the Company may
also sell debt instruments, not presently authorized, as part of its current
funding efforts. It is anticipated such private placement funding would be
intended to raise approximately $10,000,000 over the next calendar year period,
if successful. Though no amount can be warranted or assured.

Neuro may also subsequently engage in a second offering of its securities
through a registration process. It may also be required to enter into
undertakings to register stock sold in the anticipated private placement
offerings, though no arrangement or commitment as to such fundings have been
undertaken.

It is possible, though highly improbable, that the Company could obtain
commercial loans sufficient to implement its product development, but it will
make some efforts to explore the source of such funding as a supplemental source
of capital for development.

Finally, Neuro will seek out joint participation funding from other
pharmaceuticals or other related industry participants who may be willing to
finance the further development, licensing and initial marketing of the products
under a sub-license or funding agreement. The Company is most optimistic that
this may constitute a significant source of developmental funds, though it can
make no assurance or warranty of the success of such efforts which are presently
being explored through various potential industry participants.


                                        12


As noted previously, the Company may finally attempt to fund later development
and licensing of products if it obtains licensing and marketing rights of some
of the earlier products from anticipated revenues of those products, though no
assurance that such revenues or resulting funding will be available can in any
way be made or implied at this time.

As also indicated above, the lack of current capital and the contingency of
future capital resources constitutes a significant risk factor to anyone
acquiring or trading in the shares of this company at the present time. Further,
significant risks exist in that there can be no warranty or assurance that the
pharmaceutical products or procedures will ultimately be determined efficacious
or marketable.   As a result, the auditors have expressed a reservation as to
whether the Company may qualify as a going concern.


Item 3.  Controls and Procedures

     (a)  The Company maintains controls and procedures designed to ensure that
       information required to be disclosed in the reports that the Company
       files or submits under the Securities Exchange Act of 1934 is recorded,
       processed, summarized and reported within the time periods specified in
       the rules and forms of the Securities and Exchange Commission.  Based
       upon their evaluation of those controls and procedures performed within
       90 days of the filing date of this report, the chief executive officer
       and the principal financial officer of the Company, designated below,
       concluded that the Company's disclosure controls and procedures were
       adequate for its current limited activities and absence of revenues.

     (b)  Changes in internal controls.  The Company has made no significant
       changes in its internal controls since inception.  However, Neuro
       intends to adopt an independent audit committee and make further changes
       in its internal auditing and review procedures in calendar year 2003.


Item 5.  Other Matters

     (1)  Other Material Contracts.  On March 1, 2003 the Company approved in
principle an investment advisory contract with SCO Financial Group, LLC ("SCO")
of New York, New York.  SCO will assist Neuro in its continuing efforts to raise
subsequent capital and other financing efforts.  SCO will be paid a retainer of
$9,000 per month until financing is completed or the contract is terminated
after a minimum one year term.  In addition, SCO will be given warrants for
250,000 shares without further exercise costs to purchase shares at the market
price on March 1, 2003, however these will not be issued until such time that a
financing occurs.  In the event of successful financing, SCO will receive a
commission of 7% of the financing transaction plus warrants for 10% of the
shares to be issued.  Other terms of the proposed funding contract, which has
not yet been entered, are set-out in the attached and incorporated contract with
SCO.

                                        13


     (2)  Trading.  Neuro continues to have very limited trading on the
Electronic Bulletin Board for its shares since listing on 21st November 2002
under the trading symbol "NUBI".  The "bid"-"ask" price for Neuro shares during
this quarter ranged from $2.15 a bid and $5.75 asked.  Neuro should be
considered as an extremely high risk investment due to the absence of any
present business revenues and limited assets.


Item 6.  Exhibits and Reports on Form 8-K

(a)  Exhibits

     1.0  Financing Contract with SCO Financial Group, LLC

     99.1 Certification under Section 906 of the Sarbanes-Oxley Act of 2002
          (18 U.S.C. SECTION 1350)

(b)  Reports on Form 8-K

     No reports on Form 8-K were filed during the reporting period.


                                        14


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant
has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.

DATE:  May 14, 2003             By: /s/ Alan Bowen
                                    --------------------------------
                                    Mr. Alan Bowen
                                    Presidsent

DATE:  May 14, 2003             By: /s/ Lee Cole
                                    --------------------------------
                                    Mr. Lee Cole
                                    Chief Financial and Accounting Officer


                                        15


                       CERTIFICATION PURSUANT TO
                        18 U.S.C. SECTION 1350,
                        AS ADOPTED PURSUANT TO
             SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In  connection with the Quarterly Report of Neuro Bioscience,  Inc.
(the  "Company")  on Form 10-QSB for the period  ending  March  31,
2003,  as filed with the Securities and Exchange Commission on  the
date  hereof (the "Report"), we, Mr. Alan Bowen, President and  Mr.
Lee  Cole,  Chief  Financial Officer, certify to the  best  of  our
knowledge, pursuant to 18 U.S.C. Section 1350, as adopted  pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

      (1)   The  report  fully complies with  the  requirements  of
section  13 (a) or 15 (d) of the Securities Exchange Act  of  1934;
and

      (2)  The information contained in the Report fairly presents,
in  all  material respects, the financial condition and  result  of
operations of the Company.




Date:   May 14, 2003
                         /s/ Alan Bowen
                         -----------------------------
                         Mr. Alan Bowen
                         President


Date:   May 14, 2003     /s/ Lee Cole
                         -----------------------------
                         Mr. Lee Cole
                         Chief Financial Officer


                                        16




                             Attachment A

                             CERTIFICATION


I,  Alan  Bowen,  President and Director of Neuro  Bioscience,  Inc
certify that:

      (1)  I have reviewed this quarterly report on Form 10-QSB  of
Neuro Bioscience, Inc;

      (2)   Based on my knowledge, this quarterly report  does  not
contain  any untrue statement of a material fact necessary to  make
the statements made, in light of the circumstances under which such
statements  were made, not misleading with respect  to  the  period
covered by this quarterly report;

      (3)   Based  on  my knowledge, the financial statements,  and
other  financial  information included  in  this  quarterly  report
fairly  present  in all material respects the financial  condition,
results  of operations and cash flows of the registrant as of,  and
for, the periods presented in this quarterly report;

      (4)   The  registrant's other certifying officers and  I  are
responsible  for  establishing and maintaining disclosure  controls
and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14)
for the registrant and we have:

                     (a)   designed  such disclosure  controls  and
               procedures   to  ensure  that  material  information
               relating   to   the   registrant,   including    its
               consolidated subsidiaries, is made known  to  us  by
               others  within  those entities, particularly  during
               the  period in which this quarterly report is  being
               prepared;

                      (b)   evaluated  the  effectiveness  of   the
               registrant's  disclosure controls and procedures  as
               of a date within 90 days prior to the filing date of
               this quarterly report (the "Evaluation Date'); and

                     (c)   presented in this quarterly  report  our
               conclusions   about   the   effectiveness   of   the
               disclosure  controls  and procedures  based  on  our
               evaluation as of the Evaluation Date;

      (5)   The registrant's other certifying officers and  I  have
disclosed, based on our most recent evaluation, to the registrant's
auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent function):


                                        17


                    (a)  all significant deficiencies in the design
               or   operation  of  internal  controls  which  could
               adversely affect the registrant's ability to record,
               process,  summarize  and report financial  data  and
               have  identified for the registrant's  auditors  any
               material weaknesses in internal controls; and

                     (b)   any fraud, whether or not material, that
               involves  management or other employees who  have  a
               significant   role  in  the  registrant's   internal
               controls; and

      (6)   The registrant's other certifying officers and  I  have
indicated  in  this  quarterly report whether  or  not  there  were
significant  changes in internal controls or in other factors  that
could significantly affect internal controls subsequent to the date
of  our  most  recent evaluation, including any corrective  actions
with regard to significant deficiencies and material weaknesses.



               DATE:     May 14, 2003



                              /s/Alan Bowen
                              -------------------------------
                              Alan Bowen
                              President



                                        18



                             Attachment A

                             CERTIFICATION


I,  Lee  Cole,  Chief  Financial Officer of Neuro  Bioscience,  Inc
certify that:

      (1)  I have reviewed this quarterly report on Form 10-QSB  of
Neuro Bioscience, Inc.

      (2)   Based on my knowledge, this quarterly report  does  not
contain  any untrue statement of a material fact necessary to  make
the statements made, in light of the circumstances under which such
statements  were made, not misleading with respect  to  the  period
covered by this quarterly report;

      (3)   Based  on  my knowledge, the financial statements,  and
other  financial  information included  in  this  quarterly  report
fairly  present  in all material respects the financial  condition,
results  of operations and cash flows of the registrant as of,  and
for, the periods presented in this quarterly report;

      (4)   The  registrant's other certifying officers and  I  are
responsible  for  establishing and maintaining disclosure  controls
and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14)
for the registrant and we have:

                     (a)   designed  such disclosure  controls  and
               procedures   to  ensure  that  material  information
               relating   to   the   registrant,   including    its
               consolidated subsidiaries, is made known  to  us  by
               others  within  those entities, particularly  during
               the  period in which this quarterly report is  being
               prepared;

                      (b)   evaluated  the  effectiveness  of   the
               registrant's  disclosure controls and procedures  as
               of a date within 90 days prior to the filing date of
               this quarterly report (the "Evaluation Date'); and

                     (c)   presented in this quarterly  report  our
               conclusions   about   the   effectiveness   of   the
               disclosure  controls  and procedures  based  on  our
               evaluation as of the Evaluation Date;

      (5)   The registrant's other certifying officers and  I  have
disclosed, based on our most recent evaluation, to the registrant's
auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent function):



                                        19


                    (a)  all significant deficiencies in the design
               or   operation  of  internal  controls  which  could
               adversely affect the registrant's ability to record,
               process,  summarize  and report financial  data  and
               have  identified for the registrant's  auditors  any
               material weaknesses in internal controls; and

                     (b)   any fraud, whether or not material, that
               involves  management or other employees who  have  a
               significant   role  in  the  registrant's   internal
               controls; and

      (6)   The registrant's other certifying officers and  I  have
indicated  in  this  quarterly report whether  or  not  there  were
significant  changes in internal controls or in other factors  that
could significantly affect internal controls subsequent to the date
of  our  most  recent evaluation, including any corrective  actions
with regard to significant deficiencies and material weaknesses.



               DATE:     May 14, 2003


                              /s/ Lee Cole
                              --------------------------------
                              Lee Cole
                              Chief Financial Officer



                                        20